Clinical Annotations
To see the clinical annotation for this variant please
register or sign in.
Variant Annotations
PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed
publications. Each annotation represents information from a single paper and the goal is to report the
information that the author states, not an interpretation of the paper. The PMID for supporting PubMed
publications is found in the "Evidence" field.
Information presented, including study size, allele frequencies and statistics is taken directly from the
publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators
may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of
participants used for the calculation of the association statistics, so the number may vary slightly
from what is reported in the abstract of the paper. OMB Race Category information is derived from the
paper and mapped to standardized categories. Category definitions may be found by clicking on the
"OMB Race Category" link.
There are 24 annotations for this variant.
Register or sign in to see them.
There are 2 disease-related annotations for this variant.
Register or sign in to see them.
VIP Variant
in GSTP1
The non-synonymous polymorphism GSTP1 313A>G (I105V in exon 5, sometimes labeled GSTP1*B) has been associated with reduced enzyme activity and anticancer drug resistance and toxicity [Article:9498276, 15213713, 16707601].
The allele frequency of the GSTP1 I105V polymorphism varies widely both among and between populations [Article:11751440]. The frequency has been reported to be as low as 14% (South Africa) [Article:12435115] and as high as 53% (The Gambia) [Article:10728587]. Caucasians have an allele frequency of 28-38% [Article:15093273, 11307147], Asians 16-26% [Article:10413721], and Africans from 14-53% [Article:12435115, 10728587].
In 106 colorectal cancer patients receiving oxaliplatin, the GSTP1 I105V polymorphism was associated with survival (p=0.072) [Article:15213713] and increased risk of progression (p=0.018) [Article:15213713].
In 108 NSCLC patients treated with platinum therapy, a decreased risk was found for neutropenia in patients with the GSTP1 105V allele (p=0.02) [Article:17409936]. However, in 166 colorectal cancer patients receiving oxaliplatin and 5-fluorouracil, the GSTP1 105V allele was associated with increased risk of neutropenia [Article:17401013].
A recent study also identified GSTP1 I105V as a risk factor for the early onset of neurotoxicity from oxaliplatin treatment in colorectal cancer patients (Grothey et al., ASCO 2005), and in 90 patients receiving oxaliplatin, the risk of neuropathy was significantly higher in patients homozygous for the GSTP1 105I allele (p= 0.02) [Article:16707601].
Appendix
| Genomic Variant & GenBank ID: | 2627A>G on M24485 |
|---|
| mRNA Variant & GenBank ID: | 342A>G on NM_000852 |
|---|
| Protein Variant & GenBank ID: | I105V on NP_000843 |
|---|
Publications related to rs1695 at chr11:67352689: 25
The following icons indicate that data of a certain type is available:
-
DG
Dosing Guideline information is available
-
DL
Drug Label information is available
-
CA
High-level Clinical Annotation is available
-
VA
Variant Annotation is available
-
VIP
VIP information is available
-
PW
Pathway is available
[ close ]
|
|
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012. Khrunin Andrey, et al. [Article:22188361@PubMed] |
|
|
Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chinese medical journal. 2011. Zhang Bai-Lin, et al. [Article:21362365@PubMed] |
|
|
Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S-transferase genotypes. Mutation research. 2011. Ramos D L, et al. [Article:21640195@PubMed] |
|
|
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011. Lamas Maria J, et al. [Article:21449681@PubMed] |
|
|
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. British journal of clinical pharmacology. 2010. Etienne-Grimaldi Marie-Christine, et al. [Article:20078613@PubMed] |
|
|
GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genetics and molecular research : GMR. 2010. Oliveira A L, et al. [Article:20568049@PubMed] |
|
|
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. McLeod Howard L, et al. [Article:20530282@PubMed] |
|
|
Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics. 2010. Funke Silvia, et al. [Article:20017670@PubMed] |
|
|
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal. 2010. Khrunin A V, et al. [Article:19786980@PubMed] |
|
|
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecologic oncology. 2009. Kim Hee Seung, et al. [Article:19203783@PubMed] |
|
|
Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. The Laryngoscope. 2009. Grau Juan J, et al. [Article:19504558@PubMed] |
|
|
Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. Drugs & aging. 2008. Agostini Marco, et al. [Article:18540691@PubMed] |
|
|
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007. Kishi Shinji, et al. [Article:17264302@PubMed] |
|
|
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Ruzzo Annamaria, et al. [Article:17401013@PubMed] |
|
|
Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. Journal of human genetics. 2007. Imanishi Hiroyuki, et al. [Article:17180579@PubMed] |
|
|
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Lecomte Thierry, et al. [Article:16707601@PubMed] |
|
|
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006. Booton Richard, et al. [Article:17409936@PubMed] |
|
|
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. British journal of cancer. 2004. Stoehlmacher J, et al. [Article:15213713@PubMed] |
|
|
Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke. Toxicology letters. 2004. Georgiadis P, et al. [Article:15093273@PubMed] |
|
|
Genetic polymorphism of cytochrome P450 1A1 (Cyp1A1) and glutathione transferases (M1, T1 and P1) among Africans. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2002. Dandara Collet, et al. [Article:12435115@PubMed] |
|
|
Metabolic gene polymorphism frequencies in control populations. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001. Garte S, et al. [Article:11751440@PubMed] |
|
|
Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. International journal of cancer. Journal international du cancer. 2001. Gsur A, et al. [Article:11307147@PubMed] |
|
|
Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. International journal of cancer. Journal international du cancer. 2000. Wild C P, et al. [Article:10728587@PubMed] |
|
|
Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax. 1999. Ishii T, et al. [Article:10413721@PubMed] |
|
|
Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998. Watson M A, et al. [Article:9498276@PubMed] |
Cross-References
Platform Availability
Common Searches
